The early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time, according to analysis from Australian mathematicians, clinicians, and scientists, and published the journal Nature Medicine. The researchers from the University of New South Wales s Kirby Institute, the Peter Doherty Institute for Infection and Immunity, and the University of Sydney have identified an immune correlate of vaccine protection. This has the potential to dramatically cut development times for new vaccines, by measuring neutralising antibody levels as a proxy for immune protection from COVID-19. Neutralising antibodies are tiny Y-shaped proteins produced by our body in response to infection or vaccination. They bind to the virus, reducing its ability to infect, says Dr Deborah Cromer from the Kirby Institute.
Updated Mar 09, 2021 | 16:08 IST
According to the journal, the phase 1 trial, BBV152 induced high neutralising antibody responses that remained elevated in all participants at 3 months after the second vaccination. COVID vaccine: Covaxin phase 2 trial results published, vaccine is safe and produces neutralizing antibodies | Photo Credit: iStock Images
British medical journal The Lancet on Tuesday published the phase 2 results of the Made in India COVID-19 vaccine, COVAXIN, stating that the vaccine has better reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses compared with the phase 1 trial. No severe or life-threatening adverse events were reported, it added.
Report named as Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial and 3-month follow-up of a double-blind, randomised phase 1 trial published the as
Updated Mar 01, 2021 | 11:28 IST
A recent study has found that the COVID-19 vaccine candidate from Pfizer, which is one of the frontrunners in the race, may actually be less effective in people who are overweight or obese. Pfizer COVID vaccine may be less effective in people with obesity, finds study | Photo Credit: Reuters
New Delhi: Millions of people around the world are already suffering from obesity. Obesity is known to be a risk factor for many diseases and conditions, including cancer, type 2 diabetes and heart problems. As per studies, obesity can also put you at a high risk of COVID-19, the disease caused by the novel coronavirus.
To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International